In the CRYSTAL study, the addition of cetuximab to the regimen with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) showed an increase in the response rate (57% versus 40%; p < 0.001) and median OS (23.5 versus 20.0 months; HR 0.796; p = 0.0093) in patients with tumours without KRAS mutations [20]. The gene discussed is KRAS; the disease is neoplasm.